Wuhan Hezhong Bio-Chemical Manufacture Co., Ltd.

Choosing A Professional Supplier Will Get Twice The Result !

Home
Products
About Us
Factory Tour
Quality Control
Contact Us
Request A Quote
Home ProductsPharmaceutical Intermediates

White Color Weight Loss Powder , Pharmaceutical Raw Materials Yk-11 Raw Powder

Good quality Test Sustanon 250 for sales
Good quality Test Sustanon 250 for sales
I'm Online Chat Now

White Color Weight Loss Powder , Pharmaceutical Raw Materials Yk-11 Raw Powder

China White Color Weight Loss Powder , Pharmaceutical Raw Materials Yk-11 Raw Powder supplier

Large Image :  White Color Weight Loss Powder , Pharmaceutical Raw Materials Yk-11 Raw Powder

Product Details:

Place of Origin: China
Brand Name: Simeiquan
Certification: IOS9001
Model Number: 1234

Payment & Shipping Terms:

Minimum Order Quantity: 10g
Price: 1USD
Packaging Details: disguised package
Payment Terms: T/T, Western Union, MoneyGram
Supply Ability: 1000kg/year
Contact Now
Detailed Product Description
Purity: 99% Application: Pharmaceutical Intermediates
Appearance: White Powder Product Name: YK-11
Color: White Grade: Pharmaceutcial Grade
Shelf Life: 2 Years
High Light:

active pharmaceutical ingredient

,

pharmaceutical raw materials

Quick detail:
Full Name: (17-alpha,20E) 17,20-[(1-methoxyethylidene)bis(oxy)] 3-oxo-19-norpregna-4,20-diene 21-carboxylic acid methyl ester
Product Name: sarm yk11 1370003-76-1
Specification: ≥99%
Appearance: White fine Powder

Product Description
(17α,20E)-17,20-[(1-methoxyethylidene)bis-(oxy)]-3-oxo-19-norpregna-4,20-diene-21-carboxylic acid methyl ester (YK11), which the myogenic differentiation of C2C12 myoblast cells is induced by the novel partial agonist. as well as by .

YK11 is a selective androgen receptor modulator (SARM), which activates AR without the N/C interaction. In this study, we further investigated the mechanism by which YK11 induces myogenic differentiation of C2C12 cells. The induction of key myogenic regulatory factors (MRFs), such as myogenic differentiation factor (MyoD), myogenic factor 5 (Myf5) and myogenin, was more significant in the presence of YK11 than in the presence of DHT. YK11 treatment of C2C12 cells, but not DHT, induced the expression of follistatin (Fst), and the YK11-mediated myogenic differentiation was reversed by anti-Fst antibody.

Myogenic differentiation is in reference to the products ability to block myostatin. Myostatin inhibition has been a really popular movement since the ban of most prohormones as it looks to be a relatively unexplored area for muscle growth and fat loss. There are currently a lot of claims about mystatin inhibition, but not so much factual data on these products. YK11 will have similar affects to DHT (possibly more potent) without the negatives of DHT. What this means is that the product will most likely be suppressive and require a post cycle, but not cycle support. It also won't have androgenic side affects like hair loss, acne, etc. The increase in follistatin caused by YK11 will act as an antagonist to mystatin (it will block myostatin) as well as the anabolic properties of YK11

Fuction:
It induces muscle cells to make more follistatin which is a strong myostatin inhibitor. Myostatin (also known as differentiation 8, is a myokine (protein) produced by muscle cells that acts on muscle cells to inhibit myogenesis. Myogenesis is muscle cell growth and differentiation. Research through the years show that when you block myostatin, it allows for significantly more muscle mass. So in research myostatin are researched to find cures for muscle diseases.

We expect YK11 to be more potent than SARM LGD in terms of overall growth and feel. At this time, we expect this to be the strongest SARM on the market at a regular dosing. While suppression can occur, we expect this product to have low androgenic properties and can be used by both men and women. From our experience with SARMs, we find there are less losses of on-cycle results than pro-, although typically not as potent. We do expect this product to have similar results as a moderately dosed Halodrol, without the alpha-male/androgenic feelings while on it.

Other SARMs

Name CAS NO. Usage
AICAR 2627-69-2 acts by entering nucleoside pools, significantly increasing levels of adenosine
during periods of ATP breakdown
MK2866 841205-47-8 medical prescription for prevention of cachexia, atrophy, and sarcopenia and
for Hormone or Testoserone Replacement Therapy.
MK-677 15972-10-0
for the treatment of frailty in the elderly
LGD-4033 1165910-22-4 pharmacological profile similar to that of enobosarm, Ostarine,MK-2866
GW1516 317318-70-0 For obesity, diabetes, dyslipidemia and cardiovascular disease
Andarine(S4) 401900-40-0 partial agonist, intended mainly for treatment of benign prostatic hypertrophy
SR9009 1379686-30-2 under development at The Scripps Research Institute (TSRI),
increases the level of metabolic activity in skeletal muscles of mice
RAD140 1182367-47-0 New generation for gaining mass and cutting edges
YK11 431579-34-9 YK11: a SARM and myostatin inhibitor in one
 
AC262356 870888-46-3 New SARMS
SR9011 1379686-29-9 New SARMS
S23 1010396-29-8 New SARMS
GW0742 317318-84-6 New SARMS

 

Contact Details
Wuhan Hezhong Bio-Chemical Manufacture Co., Ltd.

Contact Person: sales

Send your inquiry directly to us (0 / 3000)